131 related articles for article (PubMed ID: 37061875)
1. The behavioral profile of 49,XXXXY and the potential impact of testosterone replacement therapy.
Samango-Sprouse CA; Hamzik MP; Gropman E; Brooks MR; Powell S; Taylor AM; Sadeghin T; Gropman AL
Genet Med; 2023 Jul; 25(7):100847. PubMed ID: 37061875
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Hormonal Therapy on the Behavioral Outcomes in 47,XXY (Klinefelter Syndrome) between 7 and 12 Years of Age.
Hamzik MP; Gropman AL; Brooks MR; Powell S; Sadeghin T; Samango-Sprouse CA
Genes (Basel); 2023 Jul; 14(7):. PubMed ID: 37510306
[TBL] [Abstract][Full Text] [Related]
3. Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY.
Samango-Sprouse C; Stapleton EJ; Lawson P; Mitchell F; Sadeghin T; Powell S; Gropman AL
Am J Med Genet C Semin Med Genet; 2015 Jun; 169(2):150-7. PubMed ID: 25939399
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation and behavioral dysfunction in males with 47,XXY and 49,XXXXY: a pilot study.
Lee RS; Song SQ; Garrison-Desany HM; Carey JL; Lasutschinkow P; Zabel A; Bressler J; Gropman A; Samango-Sprouse C
Clin Epigenetics; 2021 Jul; 13(1):136. PubMed ID: 34210361
[TBL] [Abstract][Full Text] [Related]
5. Behavioral phenotype of sex chromosome aneuploidies: 48,XXYY, 48,XXXY, and 49,XXXXY.
Visootsak J; Rosner B; Dykens E; Tartaglia N; Graham JM
Am J Med Genet A; 2007 Jun; 143A(11):1198-203. PubMed ID: 17497714
[TBL] [Abstract][Full Text] [Related]
6. Speech and language development in children with 49,XXXXY syndrome.
Samango-Sprouse CA; Lasutschinkow PC; McLeod M; Porter GF; Powell S; St Laurent J; Sadeghin T; Gropman AL
Am J Med Genet A; 2021 Dec; 185(12):3567-3575. PubMed ID: 32725750
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive development and capabilities in boys with 49,XXXXY syndrome.
Gropman AL; Porter GF; Lasutschinkow PC; Sadeghin T; Tipton ES; Powell S; Samango-Sprouse CA
Am J Med Genet A; 2021 Dec; 185(12):3541-3546. PubMed ID: 32662248
[TBL] [Abstract][Full Text] [Related]
8. Effects of short-course androgen therapy on the neurodevelopmental profile of infants and children with 49,XXXXY syndrome.
Samango-Sprouse CA; Gropman AL; Sadeghin T; Kingery M; Lutz-Armstrong M; Rogol AD
Acta Paediatr; 2011 Jun; 100(6):861-5. PubMed ID: 21362043
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Cognitive and Neurodevelopmental Profile in Tetrasomies and Pentasomies: A Systematic Review.
Ricciardi G; Cammisa L; Bove R; Picchiotti G; Spaziani M; Isidori AM; Aceti F; Giacchetti N; Romani M; Sogos C
Children (Basel); 2022 Nov; 9(11):. PubMed ID: 36360447
[No Abstract] [Full Text] [Related]
10. Behavioral phenotype of 49,XXXXY syndrome: Presence of anxiety-related symptoms and intact social awareness.
Lasutschinkow PC; Gropman AL; Porter GF; Sadeghin T; Samango-Sprouse CA
Am J Med Genet A; 2020 May; 182(5):974-986. PubMed ID: 32083381
[TBL] [Abstract][Full Text] [Related]
11. 49,XXXXY syndrome: A study of neurological function in this uncommon X and Y chromosomal disorder.
Samango-Sprouse C; Lasutschinkow PC; Mitchell F; Porter GF; Hendrie P; Powell S; Sadeghin T; Gropman A
Am J Med Genet A; 2021 Dec; 185(12):3557-3566. PubMed ID: 32656941
[TBL] [Abstract][Full Text] [Related]
12. Case of XXXXY syndrome. Development throughout adolescence and endocrine aspects.
Dötsch J; Foerster W; Holl R; Rascher W; Kiess W
Horm Res; 2000; 53(3):154-6. PubMed ID: 11044797
[TBL] [Abstract][Full Text] [Related]
13. Neurologic aspects of 49,XXXXY syndrome.
Galasso C; Arpino C; Fabbri F; Curatolo P
J Child Neurol; 2003 Jul; 18(7):501-4. PubMed ID: 12940658
[TBL] [Abstract][Full Text] [Related]
14. Behaviors of children who are exposed and not exposed to intimate partner violence: an analysis of 330 black, white, and Hispanic children.
McFarlane JM; Groff JY; O'Brien JA; Watson K
Pediatrics; 2003 Sep; 112(3 Pt 1):e202-7. PubMed ID: 12949313
[TBL] [Abstract][Full Text] [Related]
15. Adverse pathophysiological influence of early testosterone therapy on the testes of boys with higher grade sex chromosome aneuploidies (HGAs): a retrospective, cross-sectional study.
Spaziani M; Tarantino C; Pozza C; Anzuini A; Panimolle F; Papi G; Gianfrilli D; Lenzi A; Radicioni AF
J Endocrinol Invest; 2021 Jul; 44(7):1483-1490. PubMed ID: 33098655
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement in 49,XXXXY syndrome: andrological, metabolic and neurological aspects.
Mazzilli R; Delfino M; Elia J; Benedetti F; Alesi L; Chessa L; Mazzilli F
Endocrinol Diabetes Metab Case Rep; 2016; 2016():150114. PubMed ID: 26767114
[TBL] [Abstract][Full Text] [Related]
17. Hormonal & H-Y antigen studies in 49, XXXXY syndrome.
Mathews AR; Verma IC
Indian J Med Res; 1987 Feb; 85():198-201. PubMed ID: 3110059
[No Abstract] [Full Text] [Related]
18. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
Whitman BY; Myers S; Carrel A; Allen D
Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
[TBL] [Abstract][Full Text] [Related]
19. Evidence of intrauterine growth restriction and growth hormone deficiency in 49,XXXXY syndrome.
Counts DR; Yu C; Lasutschinkow PC; Sadeghin T; Gropman A; Samango-Sprouse CA
Am J Med Genet A; 2021 Dec; 185(12):3547-3553. PubMed ID: 32618131
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal perspective of hormone replacement therapies (HRTs) on neuromotor capabilities in males with 47,XXY (Klinefelter syndrome).
Samango-Sprouse C; Brooks MR; Counts D; Hamzik MP; Song S; Powell S; Sadeghin T; Gropman AL
Genet Med; 2022 Jun; 24(6):1274-1282. PubMed ID: 35341653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
